The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | DISC-0974, an anti-hemojuvelin mAb, for treating anemia in MF: results from the RALLY-MF trial
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the rationale for investigating DISC-0974, an anti-hemojuvelin monoclonal antibody (mAb), in patients with myelofibrosis (MF) and anemia, and shares findings from the Phase II RALLY-MF trial (NCT05320198). Dr Gerds highlights that anemia response improved across all patient subgroups in the trial, including those receiving JAK inhibitor therapy and transfusion-dependent patients. These data support further investigation of DISC-0974 in upcoming prospective Phase III trials. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
